11 views 0 likes

Dr. CCHMC Pediatric Surgery

GCMD Space · View profile →

Bowel Management Updates & Innovations with Live Q&A: April 2018

Video Published 2018-09-16 Updated 2026-06-10

Timestops (6)

Topic Overview

Dr. Jason Fisher and Monica Holder from Cincinnati Children's Colorectal Center present an overview of bowel management options for patients with anorectal malformations, Hirschsprung disease, spina bifida, and refractory constipation. They discuss treatment modalities including enema programs, appendicostomy (Malone procedure), sacral nerve stimulation, and Celesta injection, emphasizing individualized care through multidisciplinary collaboration. The session addresses patient and family questions about treatment efficacy, long-term medication effects, surgical options, and continence outcomes, with particular focus on when to consider surgical interventions versus conservative management.

Key Takeaways

  • Sacral deformity predicts bowel management failure with medication alone; consider enema programs earlier in these patients. (7:27)
  • Long-term Senna use is safe; melanosis coli may appear on colonoscopy but no other adverse effects documented. (24:02)
  • Chronic fleet phosphate enemas cause colonic stiffening and loss of motility; avoid long-term use. (46:28)
  • All anorectal malformation patients need lifelong urology follow-up; constipation directly impairs urinary tract function. (40:57)
  • No surgery definitively cures constipation; colon resection is last-resort and may only reduce treatment burden. (19:53)

Inside this episode

Kai, the Library's AI content creator, listened to this episode and mapped who's speaking, the chapters, key claims, and cases. Every item links to the exact moment in the recording.

AI-enriched

Who's speaking

  • Jason Fisher — guest
  • Monica Holder — guest

Chapters

  • 0:00Introduction and Program Overview — Introduction of speakers and the Cincinnati Children's Colorectal Center, including patient populations served, collaborative partnerships with urology, gynecology, GI motility, and behavioral medicine, and overview of bowel management program structure.
  • 7:06Treatment Modalities and Initial Q&A — Review of treatment options including appendicostomy/Malone procedure, Peristeen device, sacral nerve stimulator, and Celesta injection. Discussion of vomiting after enemas, sacral nerve stimulator evaluation criteria, and maximum enema volumes.
  • 17:03Surgical Options and Colon Resection — Discussion of failed pull-through procedures, colon resection considerations, effects of partial colon removal on stool consistency, and the role of motility testing. Emphasis on individualized surgical planning and resection as last-resort option.
  • 27:42Laxatives, Enema Products, and Sacral Nerve Stimulation — Detailed discussion of stimulant laxatives (Senna, Dulcolax) versus MiraLax, long-term laxative safety, enema product selection, colostomy management, and sacral nerve stimulator outcomes in pediatric patients.
  • 36:29Advanced Topics and Specific Conditions — Coverage of sacral nerve stimulation in spina bifida and deformed sacrum patients, Celesta versus Botox, continence expectations in Hirschsprung disease, potty training timelines, and anorectal malformation spectrum.
  • 51:37Closing Remarks — Acknowledgments of team members and commitment to answer remaining questions via Facebook page. Contact information provided for Cincinnati Children's Colorectal Center.

Key claims

  • 7:27Patients with deformed sacrums have lower likelihood of being successful with bowel management using medication alone, not on an enema program — Jason Fisher
  • 8:17Malone procedure typically performed starting at around age 5 years and older, most commonly between ages 5 and 10 or 12 — Jason Fisher
  • 8:53Vomiting from enemas can be caused by high volume enemas with irritants stretching the colon and causing discomfort — Jason Fisher
  • 9:14Enemas should be given either prior to meals or about an hour after a meal to prevent nausea from gastric and bowel distention — Monica Holder
  • 10:42Sacral nerve stimulators are not FDA approved for children under 18 in the United States but are performed off-label — Jason Fisher
  • 10:59Manufacturer indication for sacral nerve stimulator requires 50% improvement on symptoms — Jason Fisher
  • 13:03Maximum enema volume typically around 500 mL for rectal enemas and cecostomy/Malone enemas, occasionally slightly higher — Monica Holder
  • 17:33When portion of colon is removed, stool becomes softer or less water is absorbed; as more colon removed, stool becomes softer and looser — Jason Fisher
  • 17:28The large intestine or colon can absorb up to 1 liter of water per day in adults — Jason Fisher
  • 19:53No proven surgery absolutely works for constipation; surgery may lessen the amount of treatment needed but is not definitively curative — Jason Fisher
  • 22:31Colon resection is a big surgery requiring anastomosis with associated risks and is used as last-resort option — Jason Fisher
  • 24:02There is no research leading to scary outcomes of Senna laxative use — Monica Holder
  • 25:04Patients on long-term Senna use may show melanosis coli (freckling of colon) on colonoscopy but no other long-term side effects — Jason Fisher
  • 26:59Stimulant laxatives (Senna, Dulcolax) make the colon squeeze and push stool forward, and stool moves quicker through colon with less time to absorb water — Jason Fisher
  • 27:41MiraLax allows colon to absorb water so water stays in colon and is not absorbed, making stool softer — Jason Fisher
  • 29:04Patients with colostomy can still suffer from constipation and may need stool softener or laxative — Monica Holder
  • 33:32Peristeen device designed originally for spina bifida patients, meant for patients with dexterity problems or limited use of extremities — Monica Holder
  • 34:13Peristeen has more success in patients age 8 or older; younger patients had difficulty with balloon device staying in rectum — Monica Holder
  • 37:10Sacral nerve stimulator initially designed for urinary incontinence; during testing in postpartum women, found to also help with fecal constipation and incontinence — Jason Fisher
  • 38:03Sacral nerve stimulator works well in patients with urinary and stool issues in combination — Jason Fisher
  • 38:30No published pediatric literature details which patients sacral nerve stimulator works in and which it does not due to many variables in patient population — Jason Fisher
  • 40:57Constipation or fecal impaction puts pressure on urinary tract and can cause urinary infections, improper emptying, urgency, and other symptoms — Jason Fisher
  • 41:58All patients with anorectal malformations should be followed by urologist long-term to ensure kidney function and proper urinary tract emptying — Jason Fisher
  • 46:28Long-term use of fleet phosphate enemas can make colon irritated and stiff like a lead pipe, losing mobility and pliability — Jason Fisher
  • 47:27Celesta is hyaluronic acid polymer used as filler in patulous anus to help with fecal incontinence by making anal canal smaller — Jason Fisher
  • 48:21Celesta has little side effect with small risk of infection — Jason Fisher
  • 49:18Sacral nerve stimulator results in spina bifida patients are mixed; some respond positively, others do not — Jason Fisher
  • 50:25Sacral nerve stimulator requires 3rd sacral foramina or opening where 3rd sacral nerve exits sacrum and innervates pelvis — Jason Fisher
  • 51:57Botox is muscle relaxant that relaxes anal sphincter, typically used in Hirschsprung disease patients with higher resting anal pressures — Jason Fisher
  • 53:15Children with normal anatomy typically potty train between 2.5 to 3.5 years, sometimes even 4 years; boys tend to potty train later than girls — Monica Holder
  • 56:58Anorectal malformation is abnormal development of where colon or rectum ends up during development, with wide spectrum in male and female patients — Jason Fisher

Open questions

  • Which specific pediatric patient populations benefit most from sacral nerve stimulation versus other interventions
  • Optimal timing and criteria for transitioning patients from enemas to oral laxatives
  • Long-term developmental outcomes of MiraLax use in pediatric patients
  • Tissue regeneration approaches for anal sphincter reconstruction
  • Insurance coverage and access barriers for Peristeen device in United States
This episode was analyzed and enriched by Kai, the Library's AI content creator. Every item links to the moment it comes from — click a timestamp to listen in context.
Written for:

Pediatric Bowel Management: When the Colon Needs Help Beyond Diet and Time

The episode's main topic retold as a plain-language walkthrough — what it is, why it matters, and what the speakers concluded. Written by Kai from the episode transcript and reviewed before publishing.

For the care team · Explainer · AI-written, human-reviewed

Why This Exists

Some children cannot achieve fecal continence through typical developmental pathways. Anorectal malformations, Hirschsprung disease, spina bifida, sacrococcygeal teratomas, and refractory constipation create anatomic or neurologic barriers that diet modification and behavioral interventions cannot overcome. Pediatric bowel management programs emerged to provide these patients a structured, mechanical approach to colonic emptying — not as a temporary bridge to normal function, but often as a permanent management strategy that preserves dignity and prevents the medical complications of chronic fecal retention.

The Cincinnati Children's Colorectal Center operates as a hub coordinating urology, gynecology, GI motility, and behavioral medicine because bowel dysfunction in these populations rarely exists in isolation. Constipation or fecal impaction puts direct pressure on the urinary tract, causing infections, incomplete emptying, and urgency 40:57. All patients with anorectal malformations require long-term urologic follow-up to monitor kidney function and bladder emptying 41:58.

The Core Problem

The colon's primary function is water absorption — up to one liter daily in adults 17:28. When portions are removed, stool becomes progressively softer as less colon remains to extract water 17:33. But surgical resection is not curative for constipation 19:53. No procedure guarantees normal bowel function, and colon resection carries anastomotic risks that make it a last-resort option 22:31.

Patients with deformed sacrums have lower likelihood of success with medication alone and typically require enema-based programs 7:27. The challenge is not simply moving stool — it is achieving predictable, complete colonic emptying on a schedule that allows the patient to remain clean between treatments. "Bowel management is truly a mechanical way of emptying the colon," one discussant explained, preventing both overflow incontinence where loose stool leaks around impacted stool and the discomfort of chronic retention 7:27.

How the Approach Works

Medical Management

Stimulant laxatives — Senna and Dulcolax — make the colon contract and propel stool forward 26:59. Faster transit means less time for water absorption, producing softer stool. This differs fundamentally from MiraLax, which prevents water absorption but does not stimulate motility 27:41. For patients with impaired continence mechanisms, stimulant laxatives are preferred because loose stool from osmotic agents is harder to control 26:59.

The safety question arises daily. Long-term Senna use may produce melanosis coli — a harmless freckling visible on colonoscopy — but no research demonstrates serious adverse outcomes 24:02 25:04. "It's like insulin for a diabetic," one clinician noted. "A patient who has severe constipation needs a laxative stimulant to help move their bowels" [q5]. Doses adjust over time as the patient's physiology changes, not because of tolerance or addiction.

Enema Programs

Rectal enemas typically use volumes around 500 mL, occasionally higher, guided by contrast enema studies that map colonic distention 13:03. Timing matters: enemas given immediately after meals can cause vomiting from combined gastric and bowel distention 9:14. Administration before meals or one hour after prevents this 9:14. Warming the solution and infusing slowly over 5-15 minutes reduces discomfort and nausea.

Long-term use of fleet phosphate enemas can irritate the colon, making it stiff and less pliable — "like a lead pipe" on imaging 46:28. These are better reserved for rescue situations than daily maintenance.

The Peristeen device, originally designed for spina bifida patients, addresses dexterity limitations in patients with restricted extremity use 33:32. Success rates improve significantly in children age eight and older; younger patients struggle with balloon retention 34:13.

Surgical Options

The Malone procedure (appendicostomy) allows enema administration through the abdominal wall, typically performed from age five onward 8:17. Critical prerequisite: the patient must already be successful with rectal enemas, because the surgery only changes the route of administration, not the process itself 8:17.

Sacral nerve stimulation, FDA-approved for adults but used off-label in pediatrics, requires 50% symptom improvement to meet manufacturer criteria 10:42 10:59. It works particularly well when urinary and bowel dysfunction coexist 38:03. The device requires an intact third sacral foramen where the nerve exits to innervate the pelvis 50:25. Results in spina bifida patients are mixed — some respond, others do not 49:18.

Celesta injection uses hyaluronic acid polymer as a filler in patulous (widened) anal canals to improve continence by narrowing the opening 47:27. It carries minimal side effects beyond small infection risk 48:21. This differs from Botox, which relaxes the anal sphincter and is used primarily in Hirschsprung patients with elevated resting anal pressures 51:57.

Where Practice Is Contested

No published pediatric literature definitively predicts which patients benefit from sacral nerve stimulation 38:30. The patient population is too heterogeneous — different anatomies, different underlying diagnoses, different failure modes. Clinicians are developing pattern recognition, but surprises occur: "I put it in a patient where I really didn't think it was going to work, and it works beautifully."

Colon resection remains controversial. Before considering it, multidisciplinary evaluation should include colonic manometry to identify non-functioning segments and anorectal manometry to assess sphincter function 22:31. Even then, surgery may reduce but not eliminate the need for medical management 19:53.

When to Involve This Team

Refer when standard constipation management fails in patients with known anatomic or neurologic risk factors. Refer before considering colon resection — less invasive options may avoid major surgery. Refer when fecal incontinence persists despite behavioral interventions in a child with structural abnormalities. And refer early in patients with anorectal malformations: these children need coordinated colorectal and urologic care from the outset, not sequential consultations after complications develop.

Potty training timelines in this population differ. Children with normal anatomy typically train between 2.5 and 3.5 years, sometimes later 53:15. Children with malformations may need adequate medical management first to create the physiologic conditions that make training possible.

Takeaways from this story

  • Stimulant laxatives make colon contract and move stool faster, reducing water absorption time — preferred over MiraLax when continence is impaired.
  • Long-term Senna use is safe; melanosis coli (colon freckling) may appear on colonoscopy but causes no functional harm.
  • Malone procedure only changes enema route — patient must succeed with rectal enemas first, typically performed age 5 and older.
  • Sacral nerve stimulation works well when urinary and bowel dysfunction coexist; requires intact third sacral foramen.
  • All anorectal malformation patients need long-term urology follow-up — bowel dysfunction directly impacts urinary tract function.

Keywords

Hashtags

Transcript

Comments

Loading comments…